HOME ·

02480.HK

LUZHU BIOTECH-B (02480.HK): RSV vaccine cleared for China trial
Tags：
LUZHU BIOTECH-B02480.HKR&D Progress
2026-10-12
LUZHU BIOTECH-B(02480.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 61.62 million, loss narrowed by 20.56% YoY
Tags：
LUZHU BIOTECH-B02480.HKloss narrowed
2026-08-26
LUZHU BIOTECH-B (02480.HK): Phase III Results of Shingles Vaccine LZ901 Published in Nature Communications, Overall Vaccine Efficacy of 91.6%
Tags：
LUZHU BIOTECH-B02480.HKR&D Progress
2026-08-09